Off-Label Prescribing for Longevity: What It Means

What "off-label" means

"Off-label" means using an approved medicine in a way its official label does not list. FDA gives three examples: using the drug for a disease or condition it is not approved to treat, giving it in a different form, or giving it at a different dose. [1]

It is common and legal for clinicians to do this when they judge it appropriate. FDA says that once a drug is approved, health care providers generally may prescribe it for an unapproved use when they judge that it is medically appropriate for their patient. [1] But FDA also says it has not determined that the drug is safe and effective for the unapproved use. [1]

This page explains the concept and the evidence. It gives no dosing or use guidance, and does not tell anyone to start, stop or change a medicine. Evidence labels used: approved medicine, promising but limited, insufficient evidence, preclinical (cells/animals only). Where we looked and found nothing usable we write "Proper evidence not found."

Why prescribers use medicines off-label

FDA names two ordinary reasons: there may be no approved drug for the condition, or the patient may have tried all approved treatments without benefit. [1] Aging is not a disease or approved indication. See Is aging a disease?. Giving a medicine to a healthy person in hope of longer life is therefore different in kind from the situations FDA describes. We found no FDA statement addressing prescribing for longevity specifically. Proper evidence not found.

What professional ethics guidance says

The American Medical Association (AMA) resource page on off-label prescribing, written for the pandemic but built on its Code of Medical Ethics, says innovation should rest on sound scientific evidence and appropriate clinical expertise, involve input from colleagues, and minimize risks to individual patients. [2] It quotes the Code saying physicians should not provide therapy that, in their best judgment, cannot reasonably be expected to yield the intended clinical benefit. [2]

The AMA also lists what a physician should tell a patient to obtain explicit consent: how the approach differs from standard care, why it is recommended, known or expected risks, benefits and alternatives, experience with the use, and any conflicts of interest. [2] This is professional guidance, not law.

The two medicines most discussed

Metformin. The US label says it is indicated as an adjunct to diet and exercise to improve blood sugar control in type 2 diabetes. [3] Its label carries a boxed warning about lactic acidosis, with postmarketing cases that resulted in death. [3] For aging, a 2021 critical review concluded that the evidence that metformin extends lifespan remains controversial, and that it remains controversial whether it protects people free of disease. [4] Label: insufficient evidence for healthy people. See metformin and aging research.

Rapamycin (sirolimus). The label lists prevention of kidney transplant rejection and lymphangioleiomyomatosis. [5] It carries a boxed warning that immunosuppression increases susceptibility to infection and possible development of lymphoma and other malignancies. [5] A 2025 review of off-label rapamycin in healthy adults said that despite preclinical evidence of longer lifespan, human data have yet to establish it as a proven agent that can delay aging in healthy older adults. [6] Label: preclinical for lifespan, insufficient evidence in healthy people. See rapamycin and mTOR inhibitors.

Questions FDA suggests asking

FDA's list for a prescriber who proposes an unapproved use includes: What is the drug approved for? What scientific studies support this use? Is it likely to work better than an approved treatment? What are the benefits and risks? Is there a clinical trial I could join? [1]